Entrada Therapeutics, Inc.

**Signal Note: Baker Bros. Initiates Major Position in Entrada Therapeutics (TRDA)** **Note: The reported position value of ~$52B appears to be a data error — likely reflecting an incorrect share count or price multiplier, as Entrada's entire market cap is roughly $1B; the actual position is likely in the $50-80M range, which would still represent a significant ~5-7% ownership stake.** Baker Bros. taking a concentrated new position in Entrada is noteworthy given their track record of high-conviction bets in clinical-stage biotechs; Entrada's lead program ENTR-601 (an endosomal escape-enabled peptide conjugate for myotonic dystrophy type 1) is advancing through clinical development, with the intracellular delivery platform (ENDOSOMAL ESCAPE VEHICLE technology) representing a differentiated approach to historically undrugg